Dyckerhoff Stefan A 4

What Happened
Stefan A. Dyckerhoff, a director of Astera Labs (ALAB), sold a total of 24,998 shares in open-market transactions on April 17 and April 20, 2026, generating approximately $4,376,258 in proceeds. Transactions included multiple blocks at prices around $175.00–$175.51 per share. The sales were made pursuant to a Rule 10b5-1 trading plan adopted December 1, 2025 — indicating they were pre‑arranged dispositions rather than ad hoc trades.

Key Details

• Total sold: 24,998 shares for about $4,376,258.
• Breakout by date/price:
  • 2026-04-17: 3,253 @ $175.00 ($569,275); 7,733 @ $175.00 ($1,353,275); 613 @ $175.00 ($107,275).
  • 2026-04-20: 3,757 @ $175.12 ($657,926); 8,933 @ $175.12 ($1,564,347); 709 @ $175.12 ($124,160).
• Price details: Filing notes weighted-average prices; some shares sold in multiple trades at prices ranging $175.00–$175.01 and others $175.02–$175.51 (per footnotes).
• Footnotes of interest:
  • F1: Sales executed under a Rule 10b5-1 plan (adopted Dec 1, 2025).
  • F2/F5: Weighted-average prices with specified intra-range sale prices available on request.
  • F3–F6: Portions of shares are held in trusts/partnerships where the reporting person disclaims beneficial ownership except for pecuniary interest.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing timeliness: Form 4 filed April 21, 2026 for trades on April 17 and April 20 — no late‑filing indication in the material provided.

Context
These were sales (dispositions) under a prearranged 10b5-1 plan, which are commonly used by insiders to sell shares on a scheduled basis and do not necessarily indicate a change in the insider’s view of the company. For retail investors, note that purchases tend to be more informative about insider conviction; routine sales under 10b5-1 plans are often for portfolio or tax planning reasons.